ArticleMuscle & nerve2026
Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
aimsRozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six-week cyclic regimen may be associated with a "wearing-off" effect and disease fluctuations. We evaluated the non-cyclic administration of rozanolixizumab in patients with complex gMG.
methodsWe retrospectively studied eight patients with anti-acetylcholine receptor antibody-positive complex gMG treated at Bordeaux University Hospital. "Complex" was defined by refractoriness, contraindications, intolerance to immunosuppressants or highly active MG. Patients transitioned to weekly or fortnightly rozanolixizumab after relapse during intermittent therapy. The primary outcome was ≥ 2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at 3 months. Clinical data and serum immunoglobulin G (IgG) levels were collected at baseline, 3, 6, and 12 months.
resultsThe cohort (mean age 70.5 years; 75% female) had a mean baseline MG-ADL score of 10.8, which improved rapidly to 4.1 at 3 months. Hospitalization days dropped from 15.8/month pre-treatment to zero by 6-12 months. Corticosteroids were tapered from 30.3 to 13.3 mg/day at 1 year. Mean serum IgG levels declined by almost 50% and stabilized. Only one discontinuation occurred due to gastrointestinal symptoms; no serious infections or severe adverse events were observed. DISCUSSION: Fortnightly rozanolixizumab yielded sustained clinical benefits, reduced hospitalizations, and enabled steroid tapering in complex gMG patients. This approach may prevent cyclical relapses seen with intermittent dosing. Larger studies are needed to confirm efficacy and long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.